Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

Show other versions (1)

Bibliographic Details
Main Authors:	Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-07-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/efficacy-safety-and-cost-of-regorafenib-in-patients-with-metastatic-co-article-a5743

Similar Items

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
by: Fabien Calcagno, et al.
Published: (2016-01-01)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
by: Brice Pastor, et al.
Published: (2021-09-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.
by: Yoojoo Lim, et al.
Published: (2015-01-01)

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
by: Senar Ebinç, et al.
Published: (2022-10-01)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
by: Donghao Xu, et al.
Published: (2022-03-01)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
by: Kenji Yoshino, et al.
Published: (2017-08-01)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
by: Ali Aljubran, et al.
Published: (2019-01-01)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
by: Khan G, et al.
Published: (2014-03-01)

Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer
by: Flavia D’Angelo, et al.
Published: (2024-06-01)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
by: David Fogelman, et al.
Published: (2018-11-01)

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
by: Takeshi Kato, et al.
Published: (2023-02-01)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
by: Tang R, et al.
Published: (2015-11-01)

Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
by: Zhong J, et al.
Published: (2024-06-01)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
by: Beibei Chen, et al.
Published: (2022-12-01)

Research progress of regorafenib in the treatment of colorectal cancer
by: CHEN Yixuan, et al.
Published: (2024-09-01)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
by: Ya-Ya Deng, et al.
Published: (2023-03-01)

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study
by: Federica Martorana, et al.
Published: (2017-11-01)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01)

Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment
by: Yoshitaka Saito, et al.
Published: (2024-03-01)

A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
by: Simona De Summa, et al.
Published: (2021-11-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
by: Emaan Haque, et al.
Published: (2022-12-01)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
by: Meng-Che Hsieh, et al.
Published: (2022-05-01)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
by: Tao Yuan, et al.
Published: (2023-04-01)

Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study
by: T.-C. Wu, et al.
Published: (2024-06-01)

Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital
by: Pilar Sotoca Rubio, et al.
Published: (2024-11-01)

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
by: Marie-Laure Amram, et al.
Published: (2017-11-01)

Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
by: Prachi Bajpai, et al.
Published: (2024-07-01)

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
by: Faysal Dane, et al.
Published: (2020-03-01)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
by: Sabin Goktas Aydin, et al.
Published: (2023-11-01)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
by: Toshiki Masuishi, et al.
Published: (2019-11-01)

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases
by: Olivier Adotevi, et al.
Published: (2020-10-01)

Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data
by: Tanios Bekaii-Saab, et al.
Published: (2024-08-01)

Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis
by: Meysam Seyedifar, et al.
Published: (2024-10-01)

Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer
by: Wen‐Zhuo He, et al.
Published: (2023-03-01)

Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review
by: Yinying Wu, et al.
Published: (2020-07-01)